Jennifer K. Litton, MD, on BRCA-Mutated Breast Cancer, Changing the Standard of Care, and Treatment Sequencing

Posted: Tuesday, May 26, 2020

Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, talks about the strides made with antibody-drug conjugates for treatment of BRCA-mutated disease, improvement in quality of life, and the possibility that administering PARP inhibitors first can make immunotherapy more effective.